Moderna and Merck announced early but promising results for intismeran, a personalized mRNA vaccine that improved cancer-free survival in high-risk melanoma patients, though the data have so far only been shared via press release, ahead of peer review. Created by sequencing each patient’s tumor, the vaccine marks a significant step toward treatments designed around an individual’s biology. As medicine grows more personalized, innovations like intismeran also challenge what “standard” treatment means when no two therapies are exactly alike, raising real questions about how such individualized treatments get evaluated, priced, and made equitably accessible. Read more here.